Family medicine clinicians prescribing semaglutide or other GLP-1 receptor agonists must coordinate perioperative management carefully, as delayed gastric emptying associated with these agents increases the risk of pulmonary aspiration under anesthesia even when standard fasting protocols are followed. Current guidance from major anesthesiology societies recommends holding GLP-1 therapy prior to elective procedures, making it essential for the prescribing physician to proactively communicate with surgical and anesthesia teams rather than leaving this decision to the proceduralist. Failure to implement a clear perioperative hold protocol exposes patients to preventable airway complications and places the managing clinician in a vulnerable medicolegal position.

The available abstract does not contain sufficient clinical data to support a rigorous physician-level summary. The source appears to be a consumer health news article from NDTV rather than a peer-reviewed clinical study, and the extracted text does not include study methodology, patient population characteristics, primary or secondary endpoints, or quantitative findings.

To generate an accurate and clinically relevant summary meeting the standards appropriate for a physician audience, the full text of the source article or, preferably, the underlying primary literature being referenced would be needed. If the intent is to summarize perioperative guidance around GLP-1 receptor agonist discontinuation, there are several relevant society statements and clinical investigations on this topic, including guidance from the American Society of Anesthesiologists regarding aspiration risk and gastric motility concerns with semaglutide and other GLP-1 agents in the surgical setting. Providing the specific study, guideline document, or primary source would allow for a complete and data-supported summary.

GLP-1 receptor agonists such as semaglutide significantly slow gastric emptying, which increases the risk of retained stomach contents during anesthesia and raises the likelihood of pulmonary aspiration during surgery. Current guidance from major anesthesiology societies recommends holding these medications for a defined period before elective procedures, typically one week for weekly injectable formulations. Patients and prescribers should coordinate closely with surgical and anesthesia teams well in advance of any planned procedure to ensure appropriate medication timing. In a family medicine setting, proactively counseling GLP-1 patients to disclose their medication use during all pre-surgical consultations can prevent last-minute procedure cancellations and reduce preventable perioperative complications.

“The perioperative management of GLP-1 receptor agonists is an area where clear, proactive communication between prescribers and surgical teams can genuinely prevent harm. Delayed gastric emptying is a pharmacological reality with these medications, and the risk of pulmonary aspiration under anesthesia is not theoretical. In my practice, I make it a point to counsel every patient on a GLP-1 agent well in advance that they must disclose this medication to any anesthesiologist or surgeon, because that conversation does not always happen automatically. Getting ahead of that gap is one of the most practical things a prescribing physician can do to protect these patients.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: